Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma

Roger Gilabert-Oriol, Sebastian G.B. Furness, Brett William Stringer, Alexander Weng, Hendrik Fuchs, Bryan W Day, Angela Kourakis, Andrew W. Boyd, David L Hare, Mayank Thakur, Terrance G. Johns, Peter John Wookey

Research output: Contribution to journalArticleResearchpeer-review

Abstract

We have reported that calcitonin receptor (CTR) is widely expressed in biopsies from the lethal brain tumour glioblastoma by malignant glioma and brain tumour-initiating cells (glioma stem cells) using anti-human CTR antibodies. A monoclonal antibody against an epitope within the extracellular domain of CTR was raised (mAb2C4) and chemically conjugated to either plant ribosome-inactivating proteins (RIPs) dianthin-30 or gelonin, or the drug monomethyl auristatin E (MMAE), and purified. In the high-grade glioma cell line (HGG, representing glioma stem cells) SB2b, in the presence of the triterpene glycoside SO1861, the EC50 for mAb2C4:dianthin was 10.0 pM and for mAb2C4:MMAE [antibody drug conjugate (ADC)] 2.5 nM, 250-fold less potent. With the cell line U87MG, in the presence of SO1861, the EC50 for mAb2C4:dianthin was 20 pM, mAb2C4:gelonin, 20 pM, compared to the ADC (6.3 nM), which is >300 less potent. Several other HGG cell lines that express CTR were tested and the efficacies of mAb2C4:RIP (dianthin or gelonin) were similar. Co-administration of the enhancer SO1861 purified from plants enhances lysosomal escape. Enhancement with SO1861 increased potency of the immunotoxin (>3 log values) compared to the ADC (1 log). The uptake of antibody was demonstrated with the fluorescent conjugate mAb2C4:Alexa Fluor 568, and the release of dianthin-30:Alexa Fluor488 into the cytosol following addition of SO1861 supports our model. These data demonstrate that the immunotoxins are highly potent and that CTR is an effective target expressed by a large proportion of HGG cell lines representative of glioma stem cells and isolated from individual patients.

Original languageEnglish
Pages (from-to)1217–1228
Number of pages12
JournalCancer Immunology Immunotherapy
Volume66
Issue number9
DOIs
Publication statusPublished - 2017

Keywords

  • Calcitonin receptor
  • Glioblastoma
  • High-grade glioma cell lines
  • Immunotoxins
  • Targeting

Cite this

Gilabert-Oriol, Roger ; Furness, Sebastian G.B. ; Stringer, Brett William ; Weng, Alexander ; Fuchs, Hendrik ; Day, Bryan W ; Kourakis, Angela ; Boyd, Andrew W. ; Hare, David L ; Thakur, Mayank ; Johns, Terrance G. ; Wookey, Peter John. / Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma. In: Cancer Immunology Immunotherapy. 2017 ; Vol. 66, No. 9. pp. 1217–1228.
@article{ed335f6afcbf40059c7dc54382efb06a,
title = "Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma",
abstract = "We have reported that calcitonin receptor (CTR) is widely expressed in biopsies from the lethal brain tumour glioblastoma by malignant glioma and brain tumour-initiating cells (glioma stem cells) using anti-human CTR antibodies. A monoclonal antibody against an epitope within the extracellular domain of CTR was raised (mAb2C4) and chemically conjugated to either plant ribosome-inactivating proteins (RIPs) dianthin-30 or gelonin, or the drug monomethyl auristatin E (MMAE), and purified. In the high-grade glioma cell line (HGG, representing glioma stem cells) SB2b, in the presence of the triterpene glycoside SO1861, the EC50 for mAb2C4:dianthin was 10.0 pM and for mAb2C4:MMAE [antibody drug conjugate (ADC)] 2.5 nM, 250-fold less potent. With the cell line U87MG, in the presence of SO1861, the EC50 for mAb2C4:dianthin was 20 pM, mAb2C4:gelonin, 20 pM, compared to the ADC (6.3 nM), which is >300 less potent. Several other HGG cell lines that express CTR were tested and the efficacies of mAb2C4:RIP (dianthin or gelonin) were similar. Co-administration of the enhancer SO1861 purified from plants enhances lysosomal escape. Enhancement with SO1861 increased potency of the immunotoxin (>3 log values) compared to the ADC (1 log). The uptake of antibody was demonstrated with the fluorescent conjugate mAb2C4:Alexa Fluor 568, and the release of dianthin-30:Alexa Fluor488 into the cytosol following addition of SO1861 supports our model. These data demonstrate that the immunotoxins are highly potent and that CTR is an effective target expressed by a large proportion of HGG cell lines representative of glioma stem cells and isolated from individual patients.",
keywords = "Calcitonin receptor, Glioblastoma, High-grade glioma cell lines, Immunotoxins, Targeting",
author = "Roger Gilabert-Oriol and Furness, {Sebastian G.B.} and Stringer, {Brett William} and Alexander Weng and Hendrik Fuchs and Day, {Bryan W} and Angela Kourakis and Boyd, {Andrew W.} and Hare, {David L} and Mayank Thakur and Johns, {Terrance G.} and Wookey, {Peter John}",
year = "2017",
doi = "10.1007/s00262-017-2013-z",
language = "English",
volume = "66",
pages = "1217–1228",
journal = "Cancer Immunology Immunotherapy",
issn = "0340-7004",
publisher = "Springer-Verlag London Ltd.",
number = "9",

}

Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma. / Gilabert-Oriol, Roger; Furness, Sebastian G.B.; Stringer, Brett William; Weng, Alexander; Fuchs, Hendrik; Day, Bryan W; Kourakis, Angela; Boyd, Andrew W.; Hare, David L; Thakur, Mayank; Johns, Terrance G.; Wookey, Peter John.

In: Cancer Immunology Immunotherapy, Vol. 66, No. 9, 2017, p. 1217–1228.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma

AU - Gilabert-Oriol, Roger

AU - Furness, Sebastian G.B.

AU - Stringer, Brett William

AU - Weng, Alexander

AU - Fuchs, Hendrik

AU - Day, Bryan W

AU - Kourakis, Angela

AU - Boyd, Andrew W.

AU - Hare, David L

AU - Thakur, Mayank

AU - Johns, Terrance G.

AU - Wookey, Peter John

PY - 2017

Y1 - 2017

N2 - We have reported that calcitonin receptor (CTR) is widely expressed in biopsies from the lethal brain tumour glioblastoma by malignant glioma and brain tumour-initiating cells (glioma stem cells) using anti-human CTR antibodies. A monoclonal antibody against an epitope within the extracellular domain of CTR was raised (mAb2C4) and chemically conjugated to either plant ribosome-inactivating proteins (RIPs) dianthin-30 or gelonin, or the drug monomethyl auristatin E (MMAE), and purified. In the high-grade glioma cell line (HGG, representing glioma stem cells) SB2b, in the presence of the triterpene glycoside SO1861, the EC50 for mAb2C4:dianthin was 10.0 pM and for mAb2C4:MMAE [antibody drug conjugate (ADC)] 2.5 nM, 250-fold less potent. With the cell line U87MG, in the presence of SO1861, the EC50 for mAb2C4:dianthin was 20 pM, mAb2C4:gelonin, 20 pM, compared to the ADC (6.3 nM), which is >300 less potent. Several other HGG cell lines that express CTR were tested and the efficacies of mAb2C4:RIP (dianthin or gelonin) were similar. Co-administration of the enhancer SO1861 purified from plants enhances lysosomal escape. Enhancement with SO1861 increased potency of the immunotoxin (>3 log values) compared to the ADC (1 log). The uptake of antibody was demonstrated with the fluorescent conjugate mAb2C4:Alexa Fluor 568, and the release of dianthin-30:Alexa Fluor488 into the cytosol following addition of SO1861 supports our model. These data demonstrate that the immunotoxins are highly potent and that CTR is an effective target expressed by a large proportion of HGG cell lines representative of glioma stem cells and isolated from individual patients.

AB - We have reported that calcitonin receptor (CTR) is widely expressed in biopsies from the lethal brain tumour glioblastoma by malignant glioma and brain tumour-initiating cells (glioma stem cells) using anti-human CTR antibodies. A monoclonal antibody against an epitope within the extracellular domain of CTR was raised (mAb2C4) and chemically conjugated to either plant ribosome-inactivating proteins (RIPs) dianthin-30 or gelonin, or the drug monomethyl auristatin E (MMAE), and purified. In the high-grade glioma cell line (HGG, representing glioma stem cells) SB2b, in the presence of the triterpene glycoside SO1861, the EC50 for mAb2C4:dianthin was 10.0 pM and for mAb2C4:MMAE [antibody drug conjugate (ADC)] 2.5 nM, 250-fold less potent. With the cell line U87MG, in the presence of SO1861, the EC50 for mAb2C4:dianthin was 20 pM, mAb2C4:gelonin, 20 pM, compared to the ADC (6.3 nM), which is >300 less potent. Several other HGG cell lines that express CTR were tested and the efficacies of mAb2C4:RIP (dianthin or gelonin) were similar. Co-administration of the enhancer SO1861 purified from plants enhances lysosomal escape. Enhancement with SO1861 increased potency of the immunotoxin (>3 log values) compared to the ADC (1 log). The uptake of antibody was demonstrated with the fluorescent conjugate mAb2C4:Alexa Fluor 568, and the release of dianthin-30:Alexa Fluor488 into the cytosol following addition of SO1861 supports our model. These data demonstrate that the immunotoxins are highly potent and that CTR is an effective target expressed by a large proportion of HGG cell lines representative of glioma stem cells and isolated from individual patients.

KW - Calcitonin receptor

KW - Glioblastoma

KW - High-grade glioma cell lines

KW - Immunotoxins

KW - Targeting

UR - http://www.scopus.com/inward/record.url?scp=85019264098&partnerID=8YFLogxK

U2 - 10.1007/s00262-017-2013-z

DO - 10.1007/s00262-017-2013-z

M3 - Article

VL - 66

SP - 1217

EP - 1228

JO - Cancer Immunology Immunotherapy

JF - Cancer Immunology Immunotherapy

SN - 0340-7004

IS - 9

ER -